R132
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INFLAMMATORY_RESPONSE+0.380
- IL6_JAK_STAT3_SIGNALING+0.340
- HEDGEHOG_SIGNALING+0.330
- INTERFERON_GAMMA_RESPONSE+0.310
- UV_RESPONSE_DN+0.310
- KRAS_SIGNALING_UP+0.300
- COMPLEMENT+0.250
- APICAL_SURFACE+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.600
- MYC_TARGETS_V1-0.590
- G2M_CHECKPOINT-0.500
- OXIDATIVE_PHOSPHORYLATION-0.460
- DNA_REPAIR-0.390
- MTORC1_SIGNALING-0.360
- CHOLESTEROL_HOMEOSTASIS-0.300
- MITOTIC_SPINDLE-0.300
- P53_PATHWAY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016976 | — | — | 0.929 |
| 2 | SRR12202445 | — | — | 0.911 |
| 3 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.911 |
| 4 | TCGA-S2-AA1A-01A-12R-A39D-07 | — | cohortA1 | 0.910 |
| 5 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.909 |
| 6 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.907 |
| 7 | TCGA-CN-5358-01A-01R-1514-07 | — | — | 0.907 |
| 8 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.904 |
| 9 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.903 |
| 10 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |